scholarly journals Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

2006 ◽  
Vol 22 (4) ◽  
pp. 315-320 ◽  
Author(s):  
Miguel Santin ◽  
Evelyn Shaw ◽  
M. Jose Garcia ◽  
Antonio Delejido ◽  
Eduardo Rodriguez De Castro ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Efficacy And Safety ◽  
Interferon Α2b

scholarly journals Efficacy and safety of pegylated interferon α-2b and ribavirin in chronic hepatitis C in children

2010 ◽  
Vol 6 ◽  
pp. 341-348
Author(s):  
Joanna Kupś-Rzepecka ◽  
Violetta Gołąbek ◽  
Przemysław Kiciński ◽  
Teresa Woźniakowska-Gęsicka
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Efficacy And Safety

scholarly journals Pegylated interferon-α2b and ribavirin combination therapy for pediatric patients with chronic hepatitis C

Kanzo ◽  
2008 ◽  
Vol 49 (8) ◽  
pp. 386-388 ◽  
Author(s):  
Ayano Inui ◽  
Haruki Komatsu ◽  
Tsuyoshi Sogo ◽  
Takuji Hashimoto ◽  
Tomoo Fujisawa
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Pediatric Patients ◽  
Pegylated Interferon ◽  
Interferon Α2b

scholarly journals Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C

2008 ◽  
Vol 14 (2) ◽  
pp. 255 ◽  
Author(s):  
Celal Ayaz ◽  
Mustafa Kemal Celen ◽  
Ugur Nedim Yuce ◽  
Mehmet Faruk Geyik
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Hemodialysis Patients ◽  
Interferon Α ◽  
Efficacy And Safety

A case of deep venous thrombosis associated with pegylated interferon α2b plus ribavirin treatment of chronic hepatitis C

2007 ◽  
Vol 41 (12) ◽  
pp. 1231-1236 ◽  
Author(s):  
Chiaki Okuse ◽  
Kayo Adachi ◽  
Yoshiki Katakura ◽  
Kotaro Matsunaga ◽  
Toshiya Ishii ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Α2b

Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin

2011 ◽  
Vol 16 (7) ◽  
pp. 1081-1091 ◽  
Author(s):  
Mayumi Ueyama ◽  
◽  
Mina Nakagawa ◽  
Naoya Sakamoto ◽  
Izumi Onozuka ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interleukin 6 ◽  
Pegylated Interferon ◽  
Hepatitis C Infection ◽  
Resistance To Treatment ◽  
Interferon Α2b

scholarly journals Efficacy and safety of сepeginterferon alfa-2b in the rteatment of chronic hepatitis c in outpatients.

2018 ◽  
Vol 95 (11) ◽  
pp. 1022-1025
Author(s):  
Alexander V. Mamonov ◽  
R. A. Mamonov
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Efficacy And Safety ◽  
Results Of Treatment ◽  
Previously Treated ◽  
Outpatient Practice ◽  
High Degree

The features of the application of pegylated interferon - Сepeginterferon alfa2b (cepeg-IFN) on the results of treatment of 20 patients with chronic hepatitis C in outpatient practice. The analysis of the clinical, biochemical, virological data and transient liver elastometry on the background of antiviral therapy with cepeg-IFN. Based on these data is justified is not the worst in comparison with foreign analogues the efficacy and safety of the original domestic product for the treatment of patients with chronic hepatitis C, not previously treated with antiviral therapy, without a high degree of fibrosis or cirrhosis. Demonstrated clinical example of treatment failure associated with infection with a recombinant virus 2k1b and proposes an approach to the diagnosis of this variant infection

scholarly journals Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia

2012 ◽  
Vol 140 (7-8) ◽  
pp. 448-455
Author(s):  
Milena Bozic ◽  
Ksenija Bojovic ◽  
Milotka Fabri ◽  
Darko Nozic ◽  
Bojan Trkulja ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Multicenter Trial ◽  
Multivariable Logistic Regression Analysis ◽  
Hcv Rna ◽  
Efficacy And Safety ◽  
Specific Pcr ◽  
Adverse Affects

Introduction. Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. Pegylated interferon alfa-2a or 2b (PEG IFN alfa-2a or 2b) and ribavirin (RBV) represent a standard treatment of chronic hepatitis C (CHC). Sustained virological response (SVR), defined as continued undetectable HCV RNA 24 weeks after completion of treatment, is universally considered as an indicator of treatment efficacy. Objective. The aim of this study was to determine efficacy and safety of PEG IFN alfa-2a and RBV treatment in patients with CHC in Serbia. Methods. One hundred seventy-six patients with CHC were included in this multicenter trial from 8 reference centers in Serbia. The patients were treated with standard PEG IFN alfa- 2a and RBV protocol. We performed the following virological testing: anti-HCV (ELISA), HCV RNK (quantitative PCR), HCV genotype (type-specific PCR), HBsAg, anti-HBs, anti-HBc and anti-HIV (ELISA). Histological activity and the degree of fibrosis were determined according to the Metavir scoring system. Potential predictors for achieving SVR were evaluated using multivariable logistic regression analysis. Results. Of the treated patients with CHC 65.9% were male, and 60.2% of them aged over 40 years. Of the treated patients 68.2% had infection over 5 years, 63% had HCV RNA >400.000 IU/mL, 76.1% had HCV G1/4, and 60.1% had a mild to moderate liver fibrosis. SVR was achieved in 78.9% of patients (G1/4 79.1%; G2/3 78.1%). The factors that indicated a poorer efficacy of the treatment were age >40 (p<0.05), high basal viremia (p=0.013), and the reduction of PEG IFN alfa-2a and RBV doses, with interruption of therapy (p<0.001). Of the treated patients 45.9% had adverse affects (G1/4 50.8%; G2/3 29.7%). Conclusion. Treatment of CHC with PEG IFN alfa-2a and RBV was efficient in 78.9% of patients. The safety profile of therapy was satisfactory. Longer therapy increases the possibility of the development of adverse affects. No life-threatening adverse effects were recorded in our patients.

Sign in / Sign up

Export Citation Format

Share Document